Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (including review of TA381) [ID1296]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 January 2020
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veliparib with carboplatin and paclitaxel for untreated epithelial ovarian, fallopian tube or primary peritoneal cancer ID1561Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib for maintenance treatment of platinum-sensitive ovarian, fallopian tube and peritoneal cancer after response to 1 course of platinum-based chemotherapy [ID1680]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC